Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Boosting Blood System Protein Complex Protects Against Radiation Toxicity

By BiotechDaily International staff writers
Posted on 02 Jul 2012
New research has shown that boosting a protein pathway in the body’s blood-making system protects laboratory mice from otherwise lethal radiation poisoning.

Scientists reported findings from a multi-institutional study--posted online June 23, 2012, in the journal Nature Medicine--that open the possibility for new treatments against radiation toxicity during cancer treatment or environmental exposures--such as in a nuclear explosion or accident.

By identifying a target-specific intervention to protect the hematopoietic system against radiation toxicity, the study addresses a largely unmet challenge, according to the researchers. “These findings suggest that pharmacologic augmentation of the activity of the Thbd-aPC pathway by recombinant Thbd [thrombomodulin] or aPC [activated protein C] might offer a rational approach to the mitigation of tissue injury and lethality caused by ionizing radiation,” the scientists wrote in their article. “Recombinant human aPC has undergone extensive clinical testing in patients, and recombinant soluble human Thbd is currently being investigated for efficacy in antithrombotic therapy in humans. Our data encourage the further evaluation of these proteins for their radio-mitigating activities.”

The study revealed an earlier unknown function of the Thbd-aPC pathway in radiation mitigation. The pathway is typically known for its ability to prevent the formation of blood clots and help the body fight infections. The researchers found the pathway helps blood cells in the bone marrow recover from injury caused by radiation exposure. They demonstrated that pharmacologic boosting of this pathway with two drugs assessed for the treatment of thrombosis or infection (recombinant Thbd and aPC, respectively) can be utilized in mice to prevent death caused by exposure to lethal doses of radiation.

In all cases of treatment with recombinant soluble Thbd or aPC, the result was faster recovery of hematopoietic progenitor cell activity in bone marrow and a decrease in the harmful effects of lethal total body irradiation. When treatment was with aPC, these benefits occurred even when treatment was delayed for 24 hours. The scientists cautioned that their study involves early laboratory research in mice, so it remains to be assessed how the findings may translate to human treatment. Researchers also need to determine precisely why the protective function of the targeted Thbd-aPC protein pathway appears to function so well in mice.

Researchers noted that the protective benefits of Thbd-aPC happened only in vivo in irradiated mouse models. The researchers reported that overexpressed Thbd in irradiated laboratory cell cultures did not offer the same protective benefits, as the cells did not survive. This indicates the protective benefits of Thbd on blood making cells in irradiated mouse models depends on the help of additional cells or molecules in the body, which the researchers are trying to identify in a follow-up study.

The study involves extensive multiscientist collaborations that combined earlier independent lines of research by groups at Cincinnati Children’s Hospital Medical Center (OH, USA) and the University of Ulm (Germany), led by Hartmut Geiger, PhD, division of experimental hematology/cancer biology and the department of dermatology/allergic diseases; the University of Arkansas (Little Rock, USA), led by Martin Hauer-Jensen, MD, PhD, division of radiation Health, the College of Pharmacy and the Central Arkansas Veterans Healthcare System; the Blood Research Institute (Milwaukee, WI, USA), led by Hartmut Weiler, PhD, and The Scripps Research Institute (La Jolla, CA, USA), led by John H. Griffin, PhD, department of molecular and experimental medicine.

The researchers reported that this study reveals a global shift to multi-investigator projects that allow a combination of varied expertise by scientists tackling complicated problems from the standpoint of their respective fields. This approach requires the inclination of investigators to share unpublished data and engage in an open collaboration. The researchers also noted that the study highlights the significant of continued federal funding for cutting-edge research that can benefit human health.

Related Links:
Cincinnati Children’s Hospital Medical Center
University of Ulm
University of Arkansas



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: Neurons (greenish yellow) attach to silk-based scaffold (blue) creating functional networks throughout the scaffold pores (dark areas) (Photo courtesy of Tufts University).

Functional 3D Brain-Like Tissue Model Bioengineered

Researchers recently reported on the development of the first complex, three-dimensional (3D) model comprised of brain-like cortical tissue that displays biochemical and electrophysiologic responses, and... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.